Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Treatment and Management, Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins, and Metabolism, Diabetes, and Cancer.
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( <scp>RECAM</scp> study)
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
A global initiative to deliver precision health in diabetes
Real-world effectiveness of early insulin therapy on the incidence of cardiovascular events in newly diagnosed type 2 diabetes
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial
Asia-Pacific Perspectives on the Role of Continuous Glucose Monitoring in Optimizing Diabetes Management
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria
Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)
Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study
Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020
Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in <scp>SUSTAIN China</scp> : A 30‐week, double‐blind, phase 3a, randomized trial
Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the <scp>DISCOVER</scp> study
Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial